Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Key Inclusion Criteria:

- HCV RNA ≥ 10^4 IU/mL at screening

- HCV genotype 1, 2, 3, 4, 5, 6

- Cirrhosis determination, a fibroscan or liver biopsy may be required

- HIV-1 infection

- Use of protocol specified method(s) of contraception

- Screening laboratory values within defined thresholds

Key Exclusion Criteria:

- Clinically-significant illness (other than HCV or HIV) or any other major medical
disorder that may interfere with individual's treatment, assessment or compliance with
the protocol

- Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma
(HCC) or other malignancy (with the exception of certain resolved skin cancers)

- Screening ECG with clinically significant abnormalities

- Pregnant or nursing female or male with pregnant female partner

- Infection with hepatitis B virus (HBV)

- Use of any prohibited concomitant medications as described in the protocol

- Chronic use of systemically administered immunosuppressive agents

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.